

# Characterization of Intravenous & Oral Pharmacokinetics : NCA method


Ramesh Jayaraman, DoseQuantics Consulting

The intravenous and oral PK of DQ2 was evaluated in mice (table 1). Graphical analysis was done (figure 1) and the Non-compartmental (NCA) PK parameters were estimated (table 2).

**Table 1: Plasma mean concentration-time data of DQ2 in mice**

time (h)	Plasma conc ( $\mu\text{g}/\text{ml}$ )	
	IV PK (10 mg/kg)	POPK (10 mg/kg)
0.030	24.23	NE
0.5	16.7	4
1	11.92	4.68
2	10.41	5.73
4	9.14	6
8	5.77	4.2
17	3.82	2.08
24	2.17	1.31
32	1.12	0.64

**Figure 1: IV-PO PK curves of DQ2 in mice : log-linear plot**



**Table 2: NCA PK parameters of DQ2 in mice**

**IV PK**

Parameter	Estimate	Remark
Dose (mg/kg)	10	
$K_e (\text{h}^{-1})$	0.071	
$t_{1/2} (\text{h})$	9.71	Long half-life. Time to steady state ~ 40h
$AUC_{0-t} (\mu\text{g.h/ml})$	153	
$AUC_{0-\infty} (\mu\text{g.h/ml})$	170	To be compared with potency
$AUC_{\text{extrapol}} (\%)$	9.8	Extrapolated Area < 20%
Cl (ml/h/kg)	59	Low Clearance (1 % of Mouse Liver Blood flow ( 5.4 l/h/kg*))
$V_{ss} (\text{ml/kg})$	799	Moderate Volume of distribution (~ Mouse Total Body water = 0.725 l/kg*)

**Oral PK**

Parameter	Estimate	Remark
Dose (mg/kg)	10	
$K_e (\text{h}^{-1})$	0.078	
$t_{1/2} (\text{h})$	8.86	Long half-life. Similar to IV half-life.
$AUC_{0-t} (\mu\text{g.h/ml})$	87	
$AUC (\mu\text{g.h/ml})$	95	To be compared with potency
$AUC_{\text{extrapol}} (\%)$	8.9	Extrapolated Area < 20%
Cl/F (ml/h/kg)	105	
V/F(ml/kg)	1345	
$t_{\text{max}} (\text{h})$	4.0	Delayed absorption
$C_{\text{max}} (\mu\text{g/ml})$	6.0	To be compared with potency
F (%)	56	Moderate Bioavailability

- IVPK: DQ2 displayed low systemic clearance (1 % MLBF), moderate Volume of distribution (~total body water (0.7 l/kg)), long  $t_{1/2}$
- POPK: Delayed absorption, long  $t_{1/2}$ , oral bioavailability= 56 %
- IV and oral AUCs and  $C_{\text{max}}$  should be compared with *in vitro* potency to assess potential for efficacy & design of pharmacology studies.
- CL,  $V_{ss}$  data should be used in IVIVC analysis

1. Gabrielsson J & Weiner D. Pharmacokinetic and Pharmacodynamic data analysis: Concepts & Applications. 3<sup>rd</sup> ed. Swedish Pharmaceutical Press

2. \*Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res., 1993 10(7), 1093-1095.